ADDED
As of March 2, 2026 , the Registrant had 6,187,807 shares of common stock, $0.0001 par value per share, outstanding, comprised of 5,387,807 shares of voting common stock, $0.0001 par value per share and 800,000 shares of non-voting common stock, $0.0001 par value per share.
We have based these forward-looking statements largely on management s current expectations, estimates, forecasts and projections about our business and the industry in which we operate as well as management's beliefs and assumptions.
These statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control.
A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts, and our ability to continue as a going concern.
Our pipeline of drug candidates includes pevifoscorvir sodium (previously known as ALG-000184) for chronic HBV infection, ALG 055009 for MASH and obesity, ALG 097558 for coronavirus infections, and a portfolio of preclinical programs.
Pevifoscorvir sodium is our potential best /first in class Capsid Assembly Modulator (CAM E) for chronic HBV infection which has shown in preclinical testing to have enhanced pharmacologic properties vs.
competitor CAM E drugs and greater hepatitis B virus deoxyribonucleic acid (HBV DNA) suppression compared to the standard of care, nucleos(t)ide analogs (NAs), and has shown multi-log 10 reductions in viral antigens in a multi part Phase 1 clinical trial spanning up to 96 weeks of treatment.
ALG 055009 is our potential best in class thyroid hormone receptor beta (THR ) agonist for MASH and obesity with pharmacologic properties that appear to be enhanced based on data to date vs.
Recently presented nonclinical data suggests synergistic fat mass loss in combination with incretin receptor agonists in diet induced obese (DIO) mice.
In the area of chronic HBV infection, our most advanced drug candidate, pevifoscorvir sodium, is currently in the global Phase 2 B-Supreme study in subjects with chronic HBV infection.
REMOVED
As of March 6, 2025 , the Registrant had 6,114,311 shares of common stock, $0.0001 par value per share, outstanding, comprised of 5,314,311 shares of voting common stock, $0.0001 par value per share and 800,000 shares of non-voting common stock, $0.0001 par value per share.
We have based these forward-looking statements largely on management s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control.
A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.
Our pipeline of drug candidates includes ALG 000184 for chronic HBV infection, ALG 055009 for MASH, ALG 097558 for coronavirus infections, and a portfolio of preclinical programs.
ALG 000184 is our potential best /first in class Capsid Assembly Modulator (CAM E) for chronic HBV infection with enhanced pharmacologic properties vs.
competitor CAM E drugs and has demonstrated greater hepatitis B virus deoxyribonucleic acid (HBV DNA) suppression compared to the standard of care, nucleos(t)ide analogs (NAs), as well as multi-log 10 reductions in viral antigens in an ongoing, multi-part Phase 1 clinical trial spanning up to 96 weeks of treatment.
ALG 055009 is our potential best in class thyroid hormone receptor beta (THR ) agonist for MASH with enhanced pharmacologic properties vs.
In the area of chronic HBV infection, our most advanced drug candidate, ALG 000184, plays an important role in disrupting the HBV lifecycle with greater viral suppression as well as reductions in viral antigens, and has the potential to replace standard of care NAs and become the backbone of next-generation treatments.
We have advanced our THR agonist for MASH through a Phase 2a study and are evaluating a variety of options to fund continued development, including potential out-licensing.
There are over 296 million chronic carriers worldwide and approximately 1.5 million individuals become newly infected every year despite the availability of an efficacious prophylactic vaccine.